Total Payments
$142,066
2024 Payments
$731.08
Companies
24
Transactions
158
Medicare Patients
3,216
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$67,725 (47.7%)
Consulting$49,300 (34.7%)
Travel$14,899 (10.5%)
Food & Beverage$5,322 (3.7%)
Research$4,807 (3.4%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,425 | 15 | 45.3% |
| Consulting Fee | $49,300 | 11 | 34.7% |
| Travel and Lodging | $14,899 | 47 | 10.5% |
| Food and Beverage | $5,322 | 80 | 3.7% |
| Unspecified | $4,807 | 3 | 3.4% |
| Honoraria | $3,300 | 1 | 2.3% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$137,259
155 transactions
Research
$4,807
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $71,421 | 66 | $0 (2020) |
| Celgene Corporation | $22,694 | 17 | $0 (2019) |
| American Regent | $12,913 | 1 | $0 (2019) |
| Amgen Inc. | $8,364 | 7 | $0 (2018) |
| Allergan Inc. | $8,057 | 3 | $0 (2017) |
| INSYS Therapeutics Inc | $7,150 | 2 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,285 | 4 | $0 (2019) |
| Agios Pharmaceuticals, Inc. | $4,182 | 4 | $0 (2019) |
| Merck Sharp & Dohme LLC | $529.44 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $254.98 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $731.08 | 29 | AstraZeneca Pharmaceuticals LP ($209.30) |
| 2023 | $339.76 | 7 | ARRAY BIOPHARMA INC ($102.95) |
| 2022 | $148.96 | 4 | VIEWRAY TECHNOLOGIES INC ($81.32) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $6,601 | 7 | Daiichi Sankyo Inc. ($6,502) |
| 2019 | $35,906 | 24 | American Regent ($12,913) |
| 2018 | $23,486 | 25 | Daiichi Sankyo Inc. ($21,851) |
| 2017 | $74,841 | 61 | Daiichi Sankyo Inc. ($32,559) |
All Payment Transactions
158 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.22 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Oncology | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.70 | General |
| 10/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Oncology | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.46 | General |
| 10/09/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/07/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.11 | General |
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $1.09 | General |
| 09/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Oncology | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.45 | General |
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.87 | General |
| 08/02/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: Oncology | ||||||
| 07/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.51 | General |
| 06/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Oncology | ||||||
| 06/11/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Oncology | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.62 | General |
| 04/23/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: Oncology | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.68 | General |
| Category: ONCOLOGY | ||||||
| 04/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An open label, multicenter, single arm, Phase 1/2 trial of metronomic 5-fluorouracil in combination with nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma. (ABI-007-PANC-009) | Celgene Corporation | $2,866 | 1 |
| ABI-007-PANC-009 - An open label, multicenter, single arm, Phase 1/2 trial of metronomic 5-fluorouracil in combination with nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic | Celgene Corporation | $1,524 | 1 |
| AX-CL-COLON-PI-005277 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 601 | 50,406 | $2.2M | $283,283 |
| 2022 | 32 | 889 | 76,741 | $2.1M | $362,823 |
| 2021 | 30 | 928 | 79,685 | $1.8M | $534,160 |
| 2020 | 29 | 798 | 58,320 | $1.6M | $342,651 |
Total Patients
3,216
Total Services
265,152
Medicare Billing
$1.5M
Procedure Codes
111
All Medicare Procedures & Services
111 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 14 | 12,025 | $1.3M | $112,886 | 8.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 139 | 484 | $266,200 | $77,813 | 29.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 47 | 196 | $110,740 | $24,359 | 22.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 12,750 | $38,250 | $11,206 | 29.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $35,000 | $9,837 | 28.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 14 | 6,890 | $34,450 | $9,375 | 27.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 141 | $39,480 | $8,625 | 21.8% |
| 96416 | Administration of prolonged chemotherapy into vein | Office | 2023 | 17 | 62 | $38,440 | $7,641 | 19.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 40 | 375 | $37,500 | $5,489 | 14.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 47 | $16,450 | $5,100 | 31.0% |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 2023 | 25 | 787 | $137,725 | $2,166 | 1.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 22 | 77 | $11,550 | $2,097 | 18.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 63 | $9,450 | $1,686 | 17.8% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 17 | 55 | $5,500 | $1,017 | 18.5% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 19 | 520 | $5,200 | $1,005 | 19.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 33 | 1,230 | $67,650 | $981.82 | 1.5% |
| J9263 | Injection, oxaliplatin, 0.5 mg | Office | 2023 | 14 | 13,245 | $13,245 | $734.13 | 5.5% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 18 | 227 | $3,405 | $708.21 | 20.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 34 | $3,400 | $446.70 | 13.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 33 | 1,148 | $2,296 | $110.75 | 4.8% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2022 | 13 | 11,870 | $938,600 | $122,793 | 13.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 141 | 550 | $275,520 | $88,217 | 32.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 60 | 261 | $147,465 | $34,866 | 23.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 20 | 27,750 | $83,250 | $24,821 | 29.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2022 | 18 | 10,920 | $54,600 | $14,689 | 26.9% |
About Dr. Allyson Ocean, MD
Dr. Allyson Ocean, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366530636.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allyson Ocean, MD has received a total of $142,066 in payments from pharmaceutical and medical device companies, with $731.08 received in 2024. These payments were reported across 158 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($64,425).
As a Medicare-enrolled provider, Ocean has provided services to 3,216 Medicare beneficiaries, totaling 265,152 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 111 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Medical Oncology
- Location New York, NY
- Active Since 10/11/2006
- Last Updated 09/14/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1366530636
Products in Payments
- INJECTAFER (Drug) $84,334
- Abraxane (Drug) $18,694
- Vectibix (Biological) $8,364
- SYNDROS (Drug) $7,150
- Vitrakvi (Drug) $5,285
- TIBSOVO (Drug) $4,182
- Onivyde (Drug) $180.34
- Xermelo (Drug) $129.52
- KEYTRUDA (Biological) $115.40
- Avastin (Biological) $111.22
- MEKTOVI (Drug) $102.95
- Optune (Device) $98.68
- LUTATHERA (Drug) $94.73
- MRIdian LINAC (Device) $81.32
- Lenvima (Drug) $68.26
- LONSURF (Drug) $55.42
- Somatuline Depot 120mg-.5ml (Drug) $45.80
- CREON (Drug) $44.52
- IMFINZI (Biological) $22.50
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $21.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M